DK3079667T3 - Farmaceutiske doseringsformer - Google Patents

Farmaceutiske doseringsformer Download PDF

Info

Publication number
DK3079667T3
DK3079667T3 DK14819084.6T DK14819084T DK3079667T3 DK 3079667 T3 DK3079667 T3 DK 3079667T3 DK 14819084 T DK14819084 T DK 14819084T DK 3079667 T3 DK3079667 T3 DK 3079667T3
Authority
DK
Denmark
Prior art keywords
dosage forms
pharmaceutical dosage
pharmaceutical
forms
dosage
Prior art date
Application number
DK14819084.6T
Other languages
Danish (da)
English (en)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3079667T3 publication Critical patent/DK3079667T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14819084.6T 2013-12-13 2014-12-11 Farmaceutiske doseringsformer DK3079667T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (en) 2013-12-13 2014-12-11 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
DK3079667T3 true DK3079667T3 (da) 2019-09-09

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14819084.6T DK3079667T3 (da) 2013-12-13 2014-12-11 Farmaceutiske doseringsformer

Country Status (33)

Country Link
US (3) US10278969B2 (enExample)
EP (2) EP3079667B1 (enExample)
JP (2) JP6522619B2 (enExample)
KR (1) KR102349893B1 (enExample)
CN (2) CN105813635A (enExample)
AR (1) AR098716A1 (enExample)
AU (1) AU2014362999B2 (enExample)
CA (1) CA2930055C (enExample)
CL (1) CL2016001436A1 (enExample)
CY (1) CY1122063T1 (enExample)
DK (1) DK3079667T3 (enExample)
EA (1) EA036288B1 (enExample)
EC (1) ECSP16060194A (enExample)
ES (1) ES2745983T3 (enExample)
HR (1) HRP20191691T1 (enExample)
HU (1) HUE045156T2 (enExample)
IL (1) IL245705B (enExample)
LT (1) LT3079667T (enExample)
MA (1) MA39175A1 (enExample)
MX (1) MX2016007652A (enExample)
MY (1) MY194303A (enExample)
NZ (2) NZ719865A (enExample)
PE (1) PE20160851A1 (enExample)
PH (1) PH12016501039B1 (enExample)
PL (1) PL3079667T3 (enExample)
PT (1) PT3079667T (enExample)
RS (1) RS59270B1 (enExample)
SG (1) SG10202104627UA (enExample)
SI (1) SI3079667T1 (enExample)
TN (1) TN2016000207A1 (enExample)
TW (2) TWI721938B (enExample)
WO (1) WO2015087283A1 (enExample)
ZA (1) ZA201603064B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP4262774A4 (en) * 2020-12-18 2024-11-13 QED Therapeutics, Inc. METHODS FOR TREATING ACHINDROPLASIA
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ES2610931T3 (es) 2011-07-01 2017-05-04 Novartis Ag Terapia de combinación
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
KR102349893B1 (ko) 2022-01-10
TN2016000207A1 (en) 2017-10-06
IL245705B (en) 2021-05-31
US20200054632A1 (en) 2020-02-20
HUE045156T2 (hu) 2019-12-30
US20170007602A1 (en) 2017-01-12
JP2017502941A (ja) 2017-01-26
ECSP16060194A (es) 2019-07-31
CA2930055A1 (en) 2015-06-18
JP6522619B2 (ja) 2019-05-29
PH12016501039A1 (en) 2016-07-04
JP2019142927A (ja) 2019-08-29
US10278969B2 (en) 2019-05-07
PH12016501039B1 (en) 2024-01-19
EP3597179A1 (en) 2020-01-22
PE20160851A1 (es) 2016-09-14
HK1223833A1 (en) 2017-08-11
AU2014362999A1 (en) 2016-05-26
CL2016001436A1 (es) 2017-02-10
LT3079667T (lt) 2019-09-10
NZ760002A (en) 2022-07-29
CN116942629A (zh) 2023-10-27
NZ719865A (en) 2022-07-29
EP3079667A1 (en) 2016-10-19
MA39175A1 (fr) 2017-10-31
EA201691231A1 (ru) 2016-10-31
SI3079667T1 (sl) 2019-10-30
IL245705A0 (en) 2016-07-31
ES2745983T3 (es) 2020-03-04
HRP20191691T1 (hr) 2019-12-27
CY1122063T1 (el) 2020-11-25
PT3079667T (pt) 2019-10-10
EA036288B1 (ru) 2020-10-22
US11160804B2 (en) 2021-11-02
TWI800759B (zh) 2023-05-01
WO2015087283A1 (en) 2015-06-18
TW202128137A (zh) 2021-08-01
TWI721938B (zh) 2021-03-21
TW201605494A (zh) 2016-02-16
AR098716A1 (es) 2016-06-08
EP3597179B1 (en) 2024-04-03
MX2016007652A (es) 2016-10-13
RS59270B1 (sr) 2019-10-31
ZA201603064B (en) 2017-07-26
KR20160096093A (ko) 2016-08-12
JP6804585B2 (ja) 2020-12-23
SG10202104627UA (en) 2021-06-29
PL3079667T3 (pl) 2020-02-28
US20220265651A1 (en) 2022-08-25
CA2930055C (en) 2023-07-04
AU2014362999B2 (en) 2017-10-12
MY194303A (en) 2022-11-27
CN105813635A (zh) 2016-07-27
EP3079667B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016009485A2 (pt) Inalador de medicamento
DK3062849T3 (da) Medikamentadministrationsanordning
HUE037275T2 (hu) Gyógyszer-kombináció
EP2972351A4 (en) IMPROVED TEST PROCEDURES
EP3750590C0 (en) THRESHOLD RELEASE ADMINISTRATION CAPSULE
DK3038674T3 (da) Medikamentafgivelsesindretning
DOS2013000177S (es) Capsulas
DK3590499T3 (da) Inhalerbare lægemidler
LT3035885T (lt) Inhaliatorius
DK3035886T3 (da) Inhalator
LT3035887T (lt) Inhaliatorius
DK2964193T3 (da) Lægemidler til oral indgivelse
IL245705A0 (en) Pharmaceutical dosage forms
DK3003401T3 (da) Farmaceutisk præparat
DK2897588T3 (da) Inhalerbart lægemiddel
EP3043648C0 (en) PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
DK2983747T3 (da) Lægemiddelindgivelsesindretning
DK3043845T3 (da) Lægemiddelfremføringsanordning
LT3046537T (lt) Farmacinis angliavandenių preparatas, skirtas terapiniam panaudojimui
HRP20171888T1 (hr) Farmaceutski pripravci
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
TH1401004646B (th) องค์ประกอบทางเภสัชกรรมชนิดรับประทาน